NCT05430607

Brief Summary

A randomized controlled trial, whereby the intervention group will participate in a 12-week running program and will also continue their routine treatment program. The control group will continue the treatment program as usual.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
18

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2022

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 5, 2022

Completed
14 days until next milestone

Study Start

First participant enrolled

April 19, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

June 24, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2023

Completed
Last Updated

June 24, 2022

Status Verified

June 1, 2022

Enrollment Period

12 months

First QC Date

April 5, 2022

Last Update Submit

June 19, 2022

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in depressive symptoms

    Depressive status will be measured using the Children Depression Inventory (CDI; Kovacs, 1992) before and after the intervention to assess the change in symptoms.

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

  • Change in anxiety symptoms

    Anxiety level will be measured by Screen for Child Anxiety Related Emotional Disorders (SCARED; Birmaher et al., 1997, 1999) before and after the intervention to assess the change in symptoms.

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

Secondary Outcomes (4)

  • Change in self compassion symptoms

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

  • Change in emotion regulation symptoms

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

  • Change in self-efficacy symptoms

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

  • self injurious behavior

    1-2 weeks before the start of the intervention and at the end of the intervention (10-11 weeks after the start of the intervention)

Other Outcomes (1)

  • therapeutic components' effect on mental health

    10-11 weeks after the start of the intervention (at the end of intervention).

Study Arms (2)

Intervention group

EXPERIMENTAL

The intervention group will participate in a 9-week running program and will also continue their routine treatment program at the psychiatric ward.

Behavioral: Running therapy

Control group

NO INTERVENTION

The control group will continue their routine treatment program at the psychiatric ward.

Interventions

Running therapyBEHAVIORAL

A 9-week running program.

Intervention group

Eligibility Criteria

Age12 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • year-olds.
  • Expected to be under observation for at least 10 weeks at time of recruitment.
  • Consent of the patients and their parents to participate in the randomized control trial

You may not qualify if:

  • Acute psychosis or manic states
  • Acute suicidality
  • Extreme physical difficulties
  • Anorexia Nervosa

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Psychiatric adolescent department, Ziv Medical Center

Safed, 1304300, Israel

Location

MeSH Terms

Conditions

Mental Disorders

Study Officials

  • Tali Bertler, PhD

    Ziv Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: 2 parallel study arms
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 5, 2022

First Posted

June 24, 2022

Study Start

April 19, 2022

Primary Completion

April 1, 2023

Study Completion

October 1, 2023

Last Updated

June 24, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

Locations